FDA Advisory Committee makes recommendation on Savaysa for the reduction in risk of stroke and systemic embolic events in patients with non-valvular atrial fibrillation
The FDA ( Food and Drug Administration ) Cardiovascular and Renal Drugs Advisory Committee voted 9 to 1 to recommend approval of once-daily Savaysa ( Edoxaban ) 60 mg dosing regimen for the reduction ...
read article